Exact Sciences Corporation (EXAS)
- Previous Close
53.33 - Open
53.00 - Bid 53.91 x 500
- Ask 54.10 x 500
- Day's Range
52.17 - 54.49 - 52 Week Range
39.97 - 72.83 - Volume
4,210,317 - Avg. Volume
2,600,516 - Market Cap (intraday)
10.185B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-5.53 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
68.81
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
www.exactsciences.com6,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: EXAS
View More
Performance Overview: EXAS
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXAS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXAS
View MoreValuation Measures
Market Cap
10.18B
Enterprise Value
11.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.54
Price/Book (mrq)
4.25
Enterprise Value/Revenue
4.21
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-36.06%
Return on Assets (ttm)
-1.76%
Return on Equity (ttm)
-36.89%
Revenue (ttm)
2.83B
Net Income Avi to Common (ttm)
-1.02B
Diluted EPS (ttm)
-5.53
Balance Sheet and Cash Flow
Total Cash (mrq)
786.17M
Total Debt/Equity (mrq)
105.93%
Levered Free Cash Flow (ttm)
167.26M
Research Analysis: EXAS
View MoreResearch Reports: EXAS
View MoreExact Sciences Earnings: Robust Growth Due to Screening, New Products Launching on Schedule
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
RatingPrice TargetExact Sciences Earnings: Guidance at the Low End of Our Expectations, but Shares Remain Attractive
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
RatingPrice TargetExact Sciences Earnings: Fair Value Estimate Reduced on Weak Results and Lower Guidance
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
RatingPrice TargetExact Sciences Earnings: Fair Value Estimate Reduced on Weak Results and Lower Guidance
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
RatingPrice Target